Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 5:12:749480.
doi: 10.3389/fgene.2021.749480. eCollection 2021.

Ten Reasons Why People With Down Syndrome are Protected From the Development of Most Solid Tumors -A Review

Affiliations
Review

Ten Reasons Why People With Down Syndrome are Protected From the Development of Most Solid Tumors -A Review

Marta Pilar Osuna-Marco et al. Front Genet. .

Abstract

People with Down syndrome have unique characteristics as a result of the presence of an extra chromosome 21. Regarding cancer, they present a unique pattern of tumors, which has not been fully explained to date. Globally, people with Down syndrome have a similar lifetime risk of developing cancer compared to the general population. However, they have a very increased risk of developing certain tumors (e.g., acute leukemia, germ cell tumors, testicular tumors and retinoblastoma) and, on the contrary, there are some other tumors which appear only exceptionally in this syndrome (e.g., breast cancer, prostate cancer, medulloblastoma, neuroblastoma and Wilms tumor). Various hypotheses have been developed to explain this situation. The genetic imbalance secondary to the presence of an extra chromosome 21 has molecular consequences at several levels, not only in chromosome 21 but also throughout the genome. In this review, we discuss the different proposed mechanisms that protect individuals with trisomy 21 from developing solid tumors: genetic dosage effect, tumor suppressor genes overexpression, disturbed metabolism, impaired neurogenesis and angiogenesis, increased apoptosis, immune system dysregulation, epigenetic aberrations and the effect of different microRNAs, among others. More research into the molecular pathways involved in this unique pattern of malignancies is still needed.

Keywords: cancer; down syndrome; metabolism; microRNA; trisomy 21; tumor suppressor genes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Hallmarks of cancer protection in DS. This diagram summarizes the ten proposed molecular mechanisms and the genes involved in those mechanisms that protect people with Down syndrome from the development of most solid tumors as a consequence of the three copies of chromosome 21. Dark blue corresponds to the role of neural development; turquoise, to the presence of tumor suppressor genes; green, to the disturbed metabolism; purple, to the increased cellular apoptosis and defective DNA repair system; red, to angiogenesis; orange, to the tumor stroma; light blue, to the impaired immune system response; light red, to epigenetics; light green, to global effects outside chromosome 21; and yellow, to non-genetic factors.
FIGURE 2
FIGURE 2
Map of chromosome 21 (HSA21) and location of the genes mentioned in the review. This figure shows the detailed structure of chromosome 21 and the exact location of the genes described in the paper.

Similar articles

Cited by

References

    1. Abbassi R., Johns T. G., Kassiou M., Munoz L. (2015). DYRK1A in Neurodegeneration and Cancer: Molecular Basis and Clinical Implications. Pharmacol. Ther. 151, 87–98. 10.1016/j.pharmthera.2015.03.004 - DOI - PubMed
    1. Aboudafir E. (2017). Trisomie 21: Perspectives actuelles de recherche de traitements. Sciences pharmaceutiques. Available at: https://hal.univ-lorraine.fr/hal-01932163/document .
    1. Antonarakis S. E., Skotko B. G., Rafii M. S., Strydom A., Pape S. E., Bianchi D. W., et al. (2020). Down Syndrome. Nat. Rev. Dis. Primers 6 (1), 9. 10.1038/s41572-019-0143-7 - DOI - PMC - PubMed
    1. Araya P., Waugh K. A., Sullivan K. D., Núñez N. G., Roselli E., Smith K. P., et al. (2019). Trisomy 21 Dysregulates T Cell Lineages toward an Autoimmunity-Prone State Associated with Interferon Hyperactivity. Proc. Natl. Acad. Sci. USA 116 (48), 24231–24241. 10.1073/pnas.1908129116 - DOI - PMC - PubMed
    1. Ayed W., Gouas L., Penault-Llorca F., Amouri A., Tchirkov A., Vago P. (2012). Trisomie 21 et cancers. Morphologie 96 (314–315), 57–66. 10.1016/j.morpho.2012.10.001 - DOI - PubMed

LinkOut - more resources